Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in Advanced Esophageal Cancer
NCT02489201Phase 2Terminated
- Sponsor
- Zelgen
- Start
- Jul 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in esophageal cancer, sponsored by Zelgen. Started Jul 2015; status: terminated.
02
Drugs
donafenib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02489201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489201.